A detailed history of Fin Trust Capital Advisors, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 407 shares of BIIB stock, worth $79,206. This represents 0.02% of its overall portfolio holdings.

Number of Shares
407
Previous 324 25.62%
Holding current value
$79,206
Previous $69,000 36.23%
% of portfolio
0.02%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$190.52 - $236.72 $15,813 - $19,647
83 Added 25.62%
407 $94,000
Q1 2024

May 02, 2024

SELL
$212.02 - $267.71 $11,661 - $14,724
-55 Reduced 14.51%
324 $69,000
Q4 2023

Feb 13, 2024

SELL
$222.59 - $267.94 $15,136 - $18,219
-68 Reduced 15.21%
379 $98,000
Q3 2023

Oct 24, 2023

BUY
$253.3 - $285.89 $102,839 - $116,071
406 Added 990.24%
447 $114,000
Q2 2022

Jul 26, 2022

BUY
$187.54 - $223.02 $5,251 - $6,244
28 Added 215.38%
41 $8,000
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $31,422 - $47,298
-133 Reduced 91.1%
13 $3,000
Q3 2020

Nov 10, 2020

SELL
$264.77 - $305.71 $57,190 - $66,033
-216 Reduced 59.67%
146 $41,000
Q2 2020

Sep 11, 2020

BUY
$258.66 - $342.55 $93,634 - $124,003
362 New
362 $97,000
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $160,369 - $212,381
-620 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$268.85 - $341.04 $48,930 - $62,069
182 Added 41.55%
620 $196,000
Q4 2019

Jan 23, 2020

BUY
$220.06 - $304.07 $22,006 - $30,407
100 Added 29.59%
438 $130,000
Q3 2019

Oct 29, 2019

BUY
$217.44 - $243.88 $19,787 - $22,193
91 Added 36.84%
338 $79,000
Q2 2019

Aug 01, 2019

SELL
$219.29 - $241.72 $7,017 - $7,735
-32 Reduced 11.47%
247 $58,000
Q1 2019

May 09, 2019

SELL
$216.71 - $338.96 $1,950 - $3,050
-9 Reduced 3.13%
279 $66,000
Q4 2018

Feb 11, 2019

BUY
$278.5 - $352.75 $80,208 - $101,592
288 New
288 $87,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fin Trust Capital Advisors, LLC Portfolio

Follow Fin Trust Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.